Gastroenterology

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

There is no additional risk of developing new cancers for patients treated with IBD medications.

For the maintenance trial, 42% and 55% of patients treated with upadacitinib 15 mg and 30 mg achieved clinical remission at week 52, compared to 14% of the placebo group.

Expert hepatologists comment on primary care providers using rifaximin to manage and prevent episodes of hepatic encephalopathy.

Arun B. Jesudian, MD, and Kimberly A. Brown, MD, highlight clinical trial data of rifaximin for the treatment of hepatic encephalopathy.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

James Williams, MS, DO, FACEP, provides insight on the importance of medication reconciliation when managing patients with hepatic encephalopathy.

Arun Jesudian, MD, and James Williams, MS, DO, FACEP, highlight precipitating factors for HE and medication compliance for the condition.

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.

In 2022, dupilumab became the first treatment approved by the US Food and Drug Administration for the treatment of patients with EoE.

In the induction trial, guselkumab resulted in a higher rate of clinical remission, as well as symptomatic remission, clinical response, endoscopic improvement, and histo-endoscopic mucosal improvement at week 12.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Kimberly A. Brown, MD, reviews the use of lactulose and rifaximin as first-line treatment of hepatic encephalopathy.

Arun B. Jesudian, MD, and Kimberly A. Brown, MD, discuss conditions that may be mistaken for hepatic encephalopathy.

An expert in emergency medicine and a transplant hepatologist consider common infections that patients with hepatic encephalopathy should be evaluated for.

Drs Arun Jesudian and James Williams discuss treatment with lactulose and rifaximin for patients with hepatic encephalopathy and clinical data on their effect on hospital length of stay.

Guselkumab induction treatment resulted in significantly greater proportions of patients achieving symptomatic remission, clinical response, endoscopy improvement, and histo-endoscopic mucosal improvement at week 12 and symptomatic remission at week 4 compared to placebo.

The sensitivity for colorectal cancer detection of the blood-based test was 83%, meeting the co-primary sensitivity endpoint.

The lowest screening completion rate was in the colonoscopy invitation group at 14.5% and the patients offered a choice were more likely to complete screening of any kind, compared to either group of patients offered only 1 screening modality.

The mean number of required reinterventions was significantly lower in the patients who received a direct endoscopic necrosectomy at index session when compared with patients who received the step-up treatment approach.

There was a significant reduction in severity score for diarrhea, constipation, abdominal pain, epigastric pain, bloating, vomiting, and acid reflux in participants who reported digestive problem improvements followed by SIM01 treatment.

Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.

Dr David Hudesman, Dr Jordan Axelrad, and Dr Jose Scher discuss strategies for managing coexisting inflammatory bowel disease and psoriatic arthritis and highlight the importance of a multidisciplinary approach to providing comprehensive care.

RBX2660 can be administered through a colonoscopy or rectally.

RBX2660 was originally approved by the FDA in 2022 and came to market in January 2023.

Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.

Recent studies have indicated that using adenoma per colonoscopy as a metric could help better forecast the risk of colon cancer.

Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.